Biblio

Author Title Type [ Year(Asc)]
Filters: Author is van Besien, Koen  [Clear All Filters]
2023
Gomez-Arteaga A, Orfali N, Pasciolla M, Baptiste A, Guindine I, Hsu J, Lin J, Mayer SA, Phillips AA, Shore TB, et al. Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD). Bone Marrow Transplant. 2023.
Plate M, Jessurun J, van Besien K. Immune reconstitution inflammatory syndrome in a patient with infection after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2023:1-3.
Alhomoud M, Chokr N, Gomez-Arteaga A, Chen Z, Escalon JG, Legasto AC, Brusca-Augello G, Yamshon S, Plate M, Zappetti D, et al. Screening Chest CT Prior to Allogenic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023.
2022
Patel C, Pasciolla M, Abramova R, Salerno D, Arteaga AGomez, Shore TB, Orafali N, Mayer S, Hsu J, Phillips AA, et al. Pre-hematopoietic stem cell transplant rituximab for Epstein-Barr Virus and post-transplant lymphoproliferative disorder prophylaxis in alemtuzumab recipients. Transplant Cell Ther. 2022.
2020
Elhadad S, Chapin J, Copertino D, van Besien K, Ahamed J, Laurence J. MASP2 levels are elevated in thrombotic microangiopathies: Association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol. 2020.
Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SRonan, van Besien K, Wagner-Johnston ND, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020;4(3):560-572.
2019
Hsu J, Chen Z, Shore T, Gergis U, Mayer S, Phillips A, Guarner D, Hsu M, Cushing MM, van Besien K. OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANT FOR ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES. Biol Blood Marrow Transplant. 2019.
2016
Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, et al. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016.
2015
Patel K, Parmar S, Shah S, Shore T, Gergis U, Mayer S, van Besien K. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplant. Biol Blood Marrow Transplant. 2015.
2014
Chapin J, Shore T, Forsberg P, Desman G, van Besien K, Laurence J. Hematopoietic Transplant-Associated Thrombotic Microangiopathy: Case Report and Review of Diagnosis and Treatments. Clin Adv Hematol Oncol. 2014;12(9):565-573.
2013
Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, et al. Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. J Clin Oncol. 2013.